In non-RT cancer cells, such as cervical cancer and glioma cells, loss of SNF5 failed to increase the expression of AURKA, and inhibition of AURKA expression did not sensitize these cells, suggesting that synthetic lethality between SNF5 and AURKA is cancer type-specific. This evidence concerns the gene SMARCB1 and central nervous system cancer.